ArticleInternational journal of ophthalmology2025
Correlations between inflammatory biomarkers in peripheral blood and branch retinal vein occlusion.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Baicalin Protects ARPE-19 Cells Against BRVO-Related Hypoxic Injury by Preserving Mitochondrial Function and Inhibiting Ferroptosis.Antioxidants (Basel, Switzerland) · 2026Article
- Red blood cell distribution width/albumin ratio (RAR): A novel predictor of retinal vein occlusion in the Turkish population (STROBE).Medicine · 2026Article
- Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the possible relationship between inflammatory biomarkers in the peripheral blood of patients with branch retinal vein occlusion (BRVO).
methodsA total of 63 BRVO patients were enrolled in this cross-sectional observational study. Meanwhile, 63 age- and gender-matched cataract patients were included as controls. Complete blood count and biochemical tests were performed, and inflammatory biomarkers including platelet to lymphocyte ratio (PLR), red blood cell distribution width to albumin ratio (RAR), neutrophil to lymphocyte ratio (NLR), systemic immune inflammation index (SII), and monocyte to high density lipoprotein cholesterol ratio (MHR) were compared between the two groups.
resultsThere were no significant differences between the two groups in terms of age, sex, and prevalence of diabetes mellitus. Compared with the controls, patients with BRVO had a higher prevalence of hypertension and higher body mass index (BMI). Red blood cell distribution width (RDW), triglycerides, MHR, NLR, and RAR were elevated, whereas lymphocyte count and high-density lipoprotein were decreased in the BRVO group. Multivariate logistic regression analysis revealed that NLR (adjusted OR=1.686, 95%CI 1.075-2.646), RAR (adjusted OR=8.930, 95%CI 1.911-41.730), and body mass index (BMI; adjusted OR=1.174, 95%CI 1.010-1.365) were significantly associated with the risk of BRVO. In the receiver operating characteristic analysis, the area under the curve for NLR, RAR, and BMI were 0.602, 0.630, and 0.603, respectively. The sensitivity and specificity were 61.9% and 60.3%, 38.1% and 82.5%, and 61.9% and 57.1%, respectively.
conclusionPeripheral blood inflammatory biomarkers are elevated in BRVO patients, suggesting systemic inflammation involvement. NLR, RAR, and BMI are positively correlated with BRVO. Monitoring NLR and RAR and strict weight control may be beneficial for the prevention and treatment of BRVO.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.